BrightSpring Health Services(BTSG) - 2025 Q4 - Annual Report

Financial Performance and Debt - The company reported a substantial debt of approximately $2.6 billion as of December 31, 2025[19]. - The company's outstanding debt as of December 31, 2025, was $2.6 billion, with $1.5 billion fixed through interest rate swap agreements[516]. - A hypothetical 1% increase in interest rates would decrease the company's net income and cash flows by $10.2 million annually based on its borrowing level as of December 31, 2025[516]. - The company expects approximately $0.8 million of losses to be reclassified into pre-tax earnings from accumulated other comprehensive income (AOCI) over the next twelve months[514]. - As of December 31, 2025, the company had interest rate swaps with a combined notional value of $1.5 billion designated as cash flow hedges[513]. Market Strategy and Growth - The company is focused on expanding its market share despite operating in a highly competitive industry[18]. - The company’s growth strategy includes identifying and successfully completing acquisitions and joint ventures[19]. - The company anticipates that the demand for homecare services will grow, influenced by labor shortages and inflation in labor costs[508]. Patient Satisfaction and Compliance - The company aims to maintain a Medication Possession Ratio (MPR) over 80% to ensure compliance under contracts with payors[10]. - The company’s Net Promoter Score (NPS) surveys indicate a score above 50 is considered "excellent" and above 80 is "world class"[10]. - The company utilizes third-party consulting services to conduct NPS surveys among patients and referring physicians[10]. - The company’s patient satisfaction for outpatient rehab services was measured by the percentage of patients satisfied with their therapy progress from April 1, 2023, to June 30, 2023[12]. Cost Management and Risks - The company faces challenges in managing healthcare costs, which are typically higher than inflation[509]. - The company is exposed to rising pharmaceutical drug costs in its Pharmacy Solutions segment due to suppliers passing along increased costs[510]. - The company has limited ability to pass on increased costs associated with services to Medicare and Medicaid patients due to fixed reimbursement rates established by federal and state laws[511]. - The company’s financial performance is subject to risks from changes in Medicare and Medicaid payment methods[18].